{"description":"Only grade 3+ toxicities were recorded for the study","eventGroups":[{"deathsNumAffected":0,"deathsNumAtRisk":15,"description":"GCSF + Placebo Patients in this group will receive GCSF 10 ug/kg s.c. daily, beginning 4 days prior to the 1st apheresis \\[days -4, -3, -2, -1\\] and continued on daily GCSF for a total of 4 apheresis or until ≥ 5 x 10\\^6 CD34+ cells/kg are collected. They will also receive oral placebo for 5 days on days -6 through -2. Patients will undergo apheresis for 300 minutes to achieve approximately 3 to 4 whole blood volumes processed. This is a standard institutional protocol for autologous HSPC collection at the MGH.\n\nGCSF\n\nPlacebo","id":"EG000","otherNumAffected":0,"otherNumAtRisk":15,"seriousNumAffected":0,"seriousNumAtRisk":15,"title":"A. GCSF + Placebo"},{"deathsNumAffected":0,"deathsNumAtRisk":15,"description":"B. GCSF + meloxicam:\n\nPatients in this group will be treated with meloxicam and GCSF in an approximate two-day staggered dose schedule as described in our preclinical studies. Meloxicam will be given orally at a dose of 15 mg/day for 5 days (days -6 through -2). GCSF at 10 ug/kg/day subcutaneously will be started on day -4 and continued daily for a total of 4 apheresis or until ≥ 5 x 10\\^6 CD34+ cells/kg are collected.\n\nGCSF\n\nmeloxicam","id":"EG001","otherNumAffected":0,"otherNumAtRisk":15,"seriousNumAffected":0,"seriousNumAtRisk":15,"title":"B. GCSF + Meloxicam"}],"frequencyThreshold":"0","timeFrame":"Up to 30 days after the last apheresis session (up to 36 days after the start of treatment or 42 days for multiple myeloma patients that received cyclophosphamide)"}